Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 3.5% - Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares were down 3.5% on Thursday . The company traded as low as $11.43 and last traded at $11.39. Approximately 74,554 shares were traded during trading, a decline of 89% from the average daily volume of 687,431 shares. The stock had previously closed at $11.81.

Analyst Ratings Changes

A number of brokerages have issued reports on STOK. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Trading Down 1.8%

The business's fifty day simple moving average is $10.22 and its 200-day simple moving average is $9.58. The firm has a market cap of $635.00 million, a P/E ratio of 14.72 and a beta of 1.09.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total transaction of $64,904.13. Following the sale, the insider now owns 25,782 shares of the company's stock, valued at $258,593.46. The trade was a 20.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. GAMMA Investing LLC raised its holdings in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at $63,000. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at $72,000. US Bancorp DE grew its position in shares of Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after purchasing an additional 11,108 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at $92,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.